Please assess the completion status of the following clinical trial:

Trial Title: Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have undergone CCP testing and patients who have not undergone CCP testing will be considered for enrollment in the study.~  1. Willing to provide written informed consent.~ 2. Males ≥65 years old.~ 3. Newly diagnosed (≤6 months), treatment-naïve patient with histologically proven localized adenocarcinoma of prostate whose initial treatment has not been decided.~ 4. Candidate for and considering AS and yet would be eligible for definitive therapy.~ 5. Favorable intermediate-risk disease, defined by the NCCN as follows:~     * predominant Gleason grade 3; AND~    * percentage of positive cores \<50%; AND~    * no more than 1 of the following NCCN intermediate-risk factors:~       * Gleason grade 7~      * T2b-T2c~      * PSA 10-20 ng/mL~ 6. Estimated life expectancy ≥10 years.~ 7. Can be monitored for disease progression according to standard of care (e.g., current NCCN guidelines).~Exclusion Criteria:~* 1. Clinical evidence of metastasis or lymph node involvement.~* 2. Received pelvic radiation prior to biopsy.~* 3. Received androgen deprivation therapy (ADT) prior to biopsy; however, 5 alpha-reductase inhibitors (5-ARIs) are permitted.~* 4. Participation in interventional clinical trials.~* 5. Patient is considering watchful waiting.~* 6. Has a known history of hypogonadism.

- Gender: MALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prolaris Testing (Type: None): Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
- No Prolaris Testing (Type: None): Patients with newly diagnosed favorable intermediate-risk localized prostate cancer who DO NOT undergo Prolaris testing

Based on this trial design, predict the completion outcome and termination type (if applicable).